Cargando…

Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study

AIMS/HYPOTHESIS: Type 2 diabetes, particularly with concomitant CVD, is associated with an increased risk of cognitive impairment. We assessed the effect on accelerated cognitive decline (ACD) of the DPP-4 inhibitor linagliptin vs the sulfonylurea glimepiride in individuals with type 2 diabetes. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biessels, Geert Jan, Verhagen, Chloë, Janssen, Jolien, van den Berg, Esther, Wallenstein, Gudrun, Zinman, Bernard, Espeland, Mark A., Johansen, Odd Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099814/ https://www.ncbi.nlm.nih.gov/pubmed/33559704 http://dx.doi.org/10.1007/s00125-021-05393-8

Ejemplares similares

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
por: Biessels, Geert Jan, et al.
Publicado: (2018)

HbA(1c), Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
por: Janssen, Jolien, et al.
Publicado: (2019)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
por: Espeland, Mark A., et al.
Publicado: (2020)

CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial
por: Nath, Baishali, et al.
Publicado: (2020)

Cognitive Impairment in Diabetes: Rationale and Design Protocol of the Cog-ID Study
por: Koekkoek, Paula S, et al.
Publicado: (2015)

Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
por: Ghosh, Sujoy, et al.
Publicado: (2020)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

How to choose the most appropriate cognitive test to evaluate cognitive complaints in primary care
por: Janssen, Jolien, et al.
Publicado: (2017)

Depressive symptoms and quality of life after screening for cognitive impairment in patients with type 2 diabetes: observations from the Cog-ID cohort study
por: Janssen, Jolien, et al.
Publicado: (2019)

People with type 2 diabetes and screen-detected cognitive impairment use acute health care services more often: observations from the COG-ID study
por: Janssen, Jolien, et al.
Publicado: (2019)

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
por: Kahn, Steven, et al.
Publicado: (2019)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

Cognitive dysfunction in diabetes: how to implement emerging guidelines
por: Biessels, Geert J., et al.
Publicado: (2019)

Brain MRI Correlates of Cognitive Dysfunction in Type 2 Diabetes: The Needle Recovered From the Haystack?
por: Biessels, Geert Jan
Publicado: (2013)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020)

Diagnosing vascular cognitive impairment: Current challenges and future perspectives
por: Biesbroek, J Matthijs, et al.
Publicado: (2022)

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)
por: Christensen, Alexander S., et al.
Publicado: (2020)

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial
por: Kraaijenhof, Jordan, et al.
Publicado: (2020)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
por: Johansen, Odd Erik, et al.
Publicado: (2012)

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial
por: Leijenaar, Jolien Fleur, et al.
Publicado: (2018)

Clinical Effectiveness and Safety of Gliclazide MR and Linagliptin Combination in the Management of Patients With T2DM and Chronic Kidney Disease (CKD) Switched From Glimepiride - a Real-World, Retrospective, Observational Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2021)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)

The clinical application of linagliptin in Asians
por: Cao, Chu-qing, et al.
Publicado: (2015)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Formulation and characterization of orodispersible tablet of glimepiride
por: Kinani, Ahmad AB Yosef, et al.
Publicado: (2022)

Incorrect description of mode of excretion of linagliptin
por: Woerle, Hans-Juergen, et al.
Publicado: (2010)

Acute Kidney Injury Associated with Linagliptin
por: Nandikanti, Deepak K., et al.
Publicado: (2016)

Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019)

A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
por: Abuhasira, Ran, et al.
Publicado: (2021)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment
por: Anirudhan, Athira, et al.
Publicado: (2023)

Glimepiride: evidence-based facts, trends, and observations
por: Basit, Abdul, et al.
Publicado: (2012)

Formulation and Evaluation of New Glimepiride Sublingual Tablets
por: Al-Madhagi, Wafa, et al.
Publicado: (2017)

Erratum: Formulation and characterization of orodispersible tablet of glimepiride
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u7urvgj4u12bmgktj5dvu08u03